Equities Analysts Issue Forecasts for ETON FY2027 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Stock analysts at HC Wainwright lowered their FY2027 EPS estimates for shares of Eton Pharmaceuticals in a report issued on Tuesday, August 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $1.28 per share for the year, down from their previous estimate of $1.83. HC Wainwright currently has a “Buy” rating and a $65.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is $0.67 per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2028 earnings at $2.23 EPS, FY2029 earnings at $4.25 EPS and FY2030 earnings at $6.53 EPS.

Several other equities research analysts also recently issued reports on the company. Craig Hallum increased their price objective on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Canaccord Genuity Group initiated coverage on shares of Eton Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating and a $60.00 price objective on the stock. Finally, Zacks Research lowered shares of Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Eton Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $54.50.

Eton Pharmaceuticals Stock Performance

Shares of Eton Pharmaceuticals stock opened at $41.58 on Thursday. Eton Pharmaceuticals has a 12 month low of $14.27 and a 12 month high of $50.18. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62. The stock has a market cap of $1.14 billion, a PE ratio of -593.92 and a beta of 0.86. The business has a fifty day simple moving average of $38.23 and a 200-day simple moving average of $28.20.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.05). The firm had revenue of $24.27 million for the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Eton Pharmaceuticals in the second quarter worth about $68,629,000. Soleus Capital Management L.P. acquired a new position in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $4,061,000. Millennium Management LLC increased its holdings in shares of Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after acquiring an additional 217,042 shares during the last quarter. Oberweis Asset Management Inc. bought a new position in shares of Eton Pharmaceuticals in the 3rd quarter valued at approximately $4,180,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Eton Pharmaceuticals by 162.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 229,790 shares of the company’s stock valued at $4,993,000 after acquiring an additional 142,094 shares in the last quarter. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Jennifer Mckie Adams sold 50,000 shares of Eton Pharmaceuticals stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at $1,624,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Krempa sold 42,797 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $33.39, for a total value of $1,428,991.83. Following the completion of the sale, the insider directly owned 25,249 shares of the company’s stock, valued at approximately $843,064.11. The trade was a 62.89% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 150,000 shares of company stock worth $4,853,921. Insiders own 16.49% of the company’s stock.

Key Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright continues to recommend buying ETON and kept its $65 target, indicating that the analyst believes the company’s longer-term growth opportunity remains intact despite the forecast reductions. Eton Pharmaceuticals stock information
• Neutral Sentiment: The analyst expects earnings to ramp over time, forecasting EPS of $1.28 in FY2027, $2.23 in FY2028, $4.25 in FY2029 and $6.53 in FY2030. However, these figures are all below prior estimates, making the growth trajectory less optimistic than previously expected.
• Neutral Sentiment: HC Wainwright’s quarterly projections call for FY2026 EPS of $0.52, followed by quarterly FY2027 EPS estimates of $0.26, $0.30, $0.36 and $0.35. The current-year consensus estimate cited in the reports ranges from $0.67 to $0.75, suggesting that the revised FY2026 forecast is below broader expectations.
• Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to $0.52 from $0.68, FY2027 to $1.28 from $1.83, FY2028 to $2.23 from $3.50, FY2029 to $4.25 from $5.85 and FY2030 to $6.53 from $8.65. The reductions imply slower or less profitable growth and could pressure valuation, particularly with ETON trading well above its 50-day and 200-day moving averages.
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from July 27, with a zero-day short-interest ratio. Because the data appears incomplete or anomalous, it provides little meaningful insight into trading sentiment.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.